Navigation Links
KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time

Research Breakthrough Will Aid in Developing Therapies to Prevent and Reverse Atherosclerotic Heart Disease

EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- KineMed, Inc., a pathway-based drug discovery and development company, announced today the first method for measuring the efflux of cholesterol from tissues in animals through the pathway known as reverse cholesterol transport (RCT). RCT is the only known mechanism by which excess cholesterol can be removed from tissues and has therefore received considerable attention as a therapeutic target for prevention and reversal of atherosclerosis. The data, presented at the Arteriosclerosis, Thrombosis and Vascular Biology Annual Meeting in Chicago, compared the effects of several therapeutic approaches on RCT in real-time, in living animals. KineMed also presented data from its researchers and their collaborators at the University of California, Berkeley and the University of California, San Francisco demonstrating that KineMed's technology successfully measured levels of efflux of cholesterol from the tissues in human subjects.

    The data were presented in posters titled,

    --  "Measurement of Cholesterol Efflux and Global Reverse Cholesterol

        Transport Rates in Vivo with Stable Isotopes", which described in

        detail the proprietary method for measuring the flow of cholesterol

        molecules out of tissues into the bloodstream and then from the

        bloodstream out of the body, and

    --  "Effect of Reconstituted HDL on Cholesterol Efflux from Tissues in

        Vivo".  This poster showed that infusion of CSL-111 (provided by CSL

        Behring AG), which is reconstituted high density lipoprotein (rHDL)

        particles, into animals increased efflux of cholesterol

        out of tissues into the bloodstream.

In addition, data were presented in an invited plenary session talk by Marc Hellerstein M.D., Ph. D., Co-founder and Chief of the Scientific Advisory Board of KineMed, as well as Professor (Calloway Chair of Human Nutrition), University of California, Berkeley, and Professor of Medicine, University of California, San Francisco. The talk was titled,

    -- "Measuring Reverse Cholesterol Transport and Insulin-Mediated Glucose

       Utilization In Vivo in Animal Models and Humans: Pathway Fluxes as

       Therapeutic Targets". This presentation reviewed the role of

       critical pathways, including RCT, in drug discovery and development.

Dr. Hellerstein stated, "The importance of measuring changes in RCT in the intact animal or patient is highlighted by recent clinical failures in the HDL/atherosclerosis field, which have left a therapeutic void. KineMed's technology can become an integral part of efforts to discover and develop promising agents that treat and reverse atherosclerosis, thereby positioning KineMed as a leader in this field."

RCT is one of the many pathways for which KineMed has the unique technology and IP to measure in intact animals and patients. The RCT technology is currently being used by KineMed and its Pharma partners in preclinical studies as a target for screening candidate compounds, validating target activity, selecting among leads, and optimizing treatment regimes. The Company is also working with Pharma partners in clinical trials to rapidly demonstrate on-mechanism therapeutic effect in patients.

About KineMed, Inc.

KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag(TM) and KineMarker(TM)) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of infl ammation and neurodegeneration.

KineMed is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease. The Company has multiple development programs with more than a dozen major pharmaceutical companies, including Bayer, Merck, Merck KGaA, Organon and Roche.

For further information about KineMed, please visit:

CONTACT: Brent Vaughan, Chief Business Officer of KineMed, Inc.,+1-510-655-6525, ext. 110, or media, Justin Jackson of Burns McClellan,+1-212-213-0006, or , for KineMed, Inc.

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):